Vilon
A synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family, studied for thymic and immune system bioregulation and geroprotective effects.
Also referenced as: KE, Lys-Glu
Also appears in: Longevity
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Vilon crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Immune. Also surfaces under Longevity for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
KE, Lys-Glu
FDA label signal · 772 trials · 4751 PubMed results
Current evidence for Vilon is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
Vilon has no clinical trials that name it and 4751 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Vilon?
Vilon is a synthetic dipeptide with the sequence Lys-Glu (KE), the shortest peptide in the Khavinson bioregulator family. It is classified as a thymus and immune system bioregulator. Despite being only two amino acids, the Khavinson group proposes it has tissue-specific biological activity.
How it works
- Immune modulation — Vilon is theorized to support thymic function and T-lymphocyte maturation through tissue-specific gene regulation (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Geroprotective effects — in the Khavinson framework, KE dipeptide is proposed to interact with DNA in thymocytes and modulate gene expression relevant to immune senescence (Khavinson, Gerontology, 2005)
- Thymic involution — the thymus progressively atrophies with age; Vilon is theorized to counteract this process, though direct evidence is limited to cell culture and animal studies from the Khavinson group
Research status
- Khavinson (2005) reviewed peptide bioregulators including the KE dipeptide (Gerontology, 51(2):70–75)
- Khavinson et al. (2002) reported effects of short peptides on thymocyte chromatin in aging (Bulletin of Experimental Biology and Medicine, 133(5):473–475)
- No independent Western replication studies or clinical trials
Key considerations
- The smallest Khavinson bioregulator — only 2 amino acids, raising questions about specificity and mechanism
- Part of the same bioregulator family as Thymalin (the full thymic extract) and Thymagen
- Available from research vendors as lyophilized powder or capsules